MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
and sale of...
$53,907K
Net cash (used in)
provided by investing...
$11,942K
Canceled cashflow
$41,965K
Net increase in
cash, cash...
-$2,509K
Canceled cashflow
$11,942K
Proceeds from the
exercise of stock options
$49K
Stock-based compensation
expense
$3,748K
Accounts payable
$2,478K
Depreciation and
amortization expense
$1,209K
Non-cash royalty revenue
-$773K
Accounts receivable
-$684K
Operating lease,
right-of-use assets
-$567K
Amortization of premiums on
marketable securities
-$302K
Non-cash interest
associated with the sale of...
$233K
Other long-term
liabilities
$9K
Purchase of marketable
securities
$41,950K
Purchase of property and
equipment
$15K
Net cash provided by
(used in) financing...
-$7,295K
Canceled cashflow
$49K
Net cash used in
operating activities
-$7,156K
Canceled cashflow
$10,003K
Payments on royalty sale
liability, net of imputed...
$7,039K
Payments for settlement
of share-based...
$305K
Net loss
-$13,091K
Prepaid expenses and
other current assets
$2,468K
Accrued expenses
-$716K
Operating lease
liabilities
-$533K
Premium paid on
marketable securities
$281K
Other long-term
assets
$51K
Income tax receivable
$19K
Back
Back
Cash Flow
ENANTA PHARMACEUTICALS INC (ENTA)
ENANTA PHARMACEUTICALS INC (ENTA)
source: myfinsight.com